Get the Daily Brief
Latest Biotech News
RNA therapeutics dealmaking accelerates in rare blood disease
Merck KGaA agreed to buy Silence Therapeutics for about $1.3 billion, aiming to bring the RNAi candidate divesiran into a pivotal pathway for polycythemia vera. The all-cash offer values Silence...
Biotech funding targets kidney gene therapy with local delivery platform
Estuary Biotherapeutics launched with $103 million, backing kidney-targeted AAV gene therapy aimed at autosomal dominant polycystic kidney disease (ADPKD). The round includes a $93 million Series...
Clinical trial result boosts oral ulcerative colitis remission push
Gilead reported Phase 2 results for emvistegrast, an oral therapy targeting inflammatory bowel disease, showing a statistically significant improvement in clinical remission for moderate-to-severe...
First-in-human GD2 CAR T trial opens for pediatric-solid-tumor targeting
Thailand launched the TARGETS first-in-human trial of an autologous second-generation GD2-targeted CAR T-cell therapy for relapsed or refractory GD2-positive solid tumors. The prospective,...
New Phase 3 readout adds a second chance after prior FDA rejection
Disc Medicine said its treatment for a rare light-sensitivity disease cleared Phase 3 endpoints, setting up a renewed path for FDA engagement after a prior rejection. The company framed the result...
Diagnostics: plasma markers move toward ALS screening precision
Emory University researchers reported that a ten-protein plasma signature can detect amyotrophic lateral sclerosis with near-perfect accuracy. The approach centers on a simple blood draw combined...
Digital health and AI in medicine: governance and safety remain unresolved
A new UK Biobank–backed initiative aims to generate an exceptionally large, high-resolution immune profiling dataset by combining IMU Biosciences’ HD Immunology platform with Waters’ flow...
Regulatory and product safety: measles and mumps vaccine viruses show anti-tumor synergy
Researchers reported that vaccine-strain measles and mumps viruses can synergistically kill colorectal cancer cells in vitro and slow tumor growth in a nude mouse xenograft model. The combination...
RNA delivery and manufacturing: preformed vesicles accelerate personalized dosing
Acuitas Therapeutics highlighted pre-formed vesicles (PFVs) as a manufacturing and logistics workaround for nucleic acid delivery. The system stores empty lipid vesicles at standard refrigeration...
Cybersecurity intersects life sciences operations
Proofpoint reported that a conference marketed as BioTold 2026—billed as a biotech event with practitioner speakers—was actually a ransomware and phishing front. The website listed credible-life...
Merck KGaA buys RNAi biotech Silence Therapeutics
Merck KGaA agreed to acquire Silence Therapeutics in a deal valued at about $1.3 billion, expanding the German pharma’s push into RNA medicines and rare, high-unmet-need diseases. The acquisition...
Sanofi partners with ScionxBio for long-acting RNA discovery screening
Sanofi struck its first partnership with ScionxBio to screen Sanofi’s mRNA candidates using ScionxBio’s platform for longer-acting RNA approaches. The collaboration is positioned around early...
A*STAR and HistoIndex team up to accelerate fibrosis drug development
Singapore’s A*STAR signed a memorandum of understanding with HistoIndex to use quantitative, AI-driven digital pathology for evaluating preclinical therapeutic candidates in fibrotic diseases. The...
Estuary Biotherapeutics raises $103M for kidney-targeted AAV gene therapy in ADPKD
Estuary Biotherapeutics launched with $103 million to develop locally delivered AAV gene therapies targeting autosomal dominant polycystic kidney disease (ADPKD). The financing includes a $93...
Nouscom lands $135M Series D to advance neoantigen cancer interception
Nouscom raised $135 million in an oversubscribed Series D round to accelerate NOUS-209, its off-the-shelf neoantigen-based immunotherapy for cancer interception. The company’s lead focus is a...
CAR T moves into solid tumors with first-in-human GD2 trial in Thailand
Thailand launched its first-in-human trial of GD2-targeted CAR T cells, using an autologous approach for patients with relapsed or refractory GD2-positive solid tumors. The TARGETS study is a...
Gilead’s oral α4β7 inhibitor emvistegrast shows Phase 2 remission signal in ulcerative colitis
Gilead reported Phase 2 results for emvistegrast (an oral α4β7 inhibitor) in moderate-to-severe ulcerative colitis, reporting symptom elimination with a statistically significant placebo-adjusted...
AI tutoring for nursing improves NCLEX-style reasoning performance
A Tulane University study found that an AI-guided clinical reasoning tutor improved nursing students’ NCLEX-style test performance while also changing how students approached questions. The system...
IMU Biosciences and UK Biobank expand large-scale immune profiling
IMU Biosciences announced a collaboration with UK Biobank to generate a high-resolution immune profiling dataset using single-cell multiomic methods and AI-based computation. The effort targets...
China restricts foreign biotech acquisitions – reported policy shift
China moved to restrict foreign biotech acquisitions, according to a STAT+ report, signaling a more restrictive regulatory posture toward inbound investment in life sciences. The change raises the...